


SZUH280

Cat. No.:	HY-152147
CAS No.:	2770263-77-7
Molecular Formula:	C ₃₆ H ₃₄ N ₈ O ₈
Molecular Weight:	706.7
Target:	PROTACs; HDAC; Apoptosis; DNA/RNA Synthesis
Pathway:	PROTAC; Cell Cycle/DNA Damage; Epigenetics; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SZUH280 is a potent and selective PROTAC HDAC8 degrader with a DC ₅₀ of 0.58 μM in A549 cells. SZUH280 induces cancer cell apoptosis. SZUH280 hampers DNA damage repair in cancer cells, promoting cellular radiosensitization ^[1] .														
IC₅₀ & Target	HDAC8 0.58 μM (DC50)														
In Vitro	<p>HDAC8 degradation induced by SZUH280 (5 μM; 20 h) is mediated by the CRBN E3 ubiquitin ligase^[1].</p> <p>SZUH280 (0.1-10 μM; 20 h) can regulate the oncogenic protein expression and suppress cancer metastasis, potentially improving the efficacy of chemotherapy in various types of cancers^[1].</p> <p>SZUH280 (0-20 μM; 72 h) inhibits A549 cell proliferation in a concentration-dependent manner and shows stronger antiproliferative effect with irradiation^[1].</p> <p>SZUH280 (0-20 μM; 72 h) induces apoptosis and arrests cell cycle at G2/M phase in A549 cells^[1].</p> <p>SZUH280 (5 μM; 24 h) hampers DNA damage repair in cancer cells when in combination with irradiation^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>A549, HCT116, HeLa and MDA-MB-231 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.1, 0.3, 1, 3 and 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>20 h</td> </tr> <tr> <td>Result:</td> <td>Efficiently induced HDAC8 degradation in a concentration-dependent manner in A549, HCT116 and HeLa cells. Reduced the IKZF1 protein levels to a lesser extent at 10 μM in A549 cells. Decreased PGM1 expression during glucose deprivation conditions in A549 cells. Decreased SMAD3 and HDAC8 protein levels in MDA-MB-231 cells.</td> </tr> </table> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>A549 cells</td> </tr> <tr> <td>Concentration:</td> <td>2.5, 5, 10 and 20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> </table>	Cell Line:	A549, HCT116, HeLa and MDA-MB-231 cells	Concentration:	0.1, 0.3, 1, 3 and 10 μM	Incubation Time:	20 h	Result:	Efficiently induced HDAC8 degradation in a concentration-dependent manner in A549, HCT116 and HeLa cells. Reduced the IKZF1 protein levels to a lesser extent at 10 μM in A549 cells. Decreased PGM1 expression during glucose deprivation conditions in A549 cells. Decreased SMAD3 and HDAC8 protein levels in MDA-MB-231 cells.	Cell Line:	A549 cells	Concentration:	2.5, 5, 10 and 20 μM	Incubation Time:	72 h
Cell Line:	A549, HCT116, HeLa and MDA-MB-231 cells														
Concentration:	0.1, 0.3, 1, 3 and 10 μM														
Incubation Time:	20 h														
Result:	Efficiently induced HDAC8 degradation in a concentration-dependent manner in A549, HCT116 and HeLa cells. Reduced the IKZF1 protein levels to a lesser extent at 10 μM in A549 cells. Decreased PGM1 expression during glucose deprivation conditions in A549 cells. Decreased SMAD3 and HDAC8 protein levels in MDA-MB-231 cells.														
Cell Line:	A549 cells														
Concentration:	2.5, 5, 10 and 20 μM														
Incubation Time:	72 h														

Result:	Effectively inhibited cell proliferation in a concentration-dependent manner with an IC ₅₀ of 9.55 μM. Co-treatment with irradiation exhibited an even stronger antiproliferative effect (with an IC ₅₀ value of about 6.04 μM).
---------	--

Apoptosis Analysis^[1]

Cell Line:	A549 cells
Concentration:	1.25, 2.5, 5, 10 and 20 μM
Incubation Time:	72 h
Result:	Effectively induced apoptosis in a dose-dependent manner.

Cell Cycle Analysis^[1]

Cell Line:	A549 cells
Concentration:	1.25, 2.5, 5, 10 and 20 μM
Incubation Time:	72 h
Result:	Induced cell cycle arrest at the G2/M phase.

In Vivo

SZUH280 (5 mg/kg; i.p.; every 5 days for 6 weeks) shows antitumor activity in an A549 nude mouse model^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID mice (severe combined immunodeficient mice), A549 model ^[1]
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection, every 5 days for 6 weeks
Result:	Exhibited a significantly greater anti-lung cancer activity in vivo than the control group. When in combination with 3 Gy irradiation, achieved a much stronger antitumor activity.

REFERENCES

[1]. Huang J, et al. Structure-Based Discovery of Selective Histone Deacetylase 8 Degraders with Potent Anticancer Activity. J Med Chem. 2022 Dec 14.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA